---
title: 'EANM guidance document: dosimetry for first-in-human studies and early phase
  clinical trials'
date: '2024-02-17'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38366197/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240217170652&v=2.18.0
source: heidelberg[Affiliation]
description: The numbers of diagnostic and therapeutic nuclear medicine agents under
  investigation are rapidly increasing. Both novel emitters and novel carrier molecules
  require careful selection of measurement procedures. This document provides guidance
  relevant to dosimetry for first-in human and early phase clinical trials of such
  novel agents. The guideline includes a short introduction to different emitters
  and carrier molecules, followed by recommendations on the methods for activity ...
disable_comments: true
---
The numbers of diagnostic and therapeutic nuclear medicine agents under investigation are rapidly increasing. Both novel emitters and novel carrier molecules require careful selection of measurement procedures. This document provides guidance relevant to dosimetry for first-in human and early phase clinical trials of such novel agents. The guideline includes a short introduction to different emitters and carrier molecules, followed by recommendations on the methods for activity ...